Home / Cancer
Cancer
| 3 min read
The POSEIDON program aims to create first-in-class synthetic sensor-based tests to detect over 30 cancers at Stage I using only non-invasive breath and urine samples.
| 2 min read
Activace platform enables targeted, genome-wide profiling of unmethylated DNA regions, providing a comprehensive view of the epigenome that can be scaled to the study of large patient cohorts
| 5 min read
Advances in allosteric inhibitors may offer a new standard of care that balances potent disease control with better tolerability and convenience.
| 3 min read
Final results from the AMPLIFY-201 phase 1 trial highlight durable T cell responses and prolonged survival in patients with colorectal and pancreatic cancer.
| 3 min read
Illumina and pharma partners will develop companion diagnostics for historically important KRAS biomarker
| 3 min read
The new diagnostic enables rapid identification of acute leukaemia patients with KMT2A rearrangements for precision therapy.
| 3 min read
Refining organoid culture methods is key to creating lifelike models for drug discovery, cancer research, and therapy testing.
| 3 min read
New research suggests an unexpected role for T cells during a tumor’s evolution from benign to malignant.
A powerful tool in modern oncology, immunotherapy doesn’t work the same for everyone. Researchers are exploring why and developing ways to improve its effectiveness.
| 2 min read
A new transformer-based model links tumor morphology with multiple genetic alterations, offering faster diagnostics and insights to guide precision oncology.
| 9 min read
Two ongoing Phase 1 trials will produce the first human data on these potentially revolutionary cancer drugs.
| 3 min read
By combining synthetic biology, computational design, and novel RNA formats, these therapies adapt in real time to disease signals, enabling previously impossible treatments.
